Sandra Walker, APRN
Nurse Practitioner · Crestwood, KYNPI 1952664179
Payments from drug & device makers
Across 470 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Lilly USA, LLC$616
- Amgen$496
- Pfizer$414
- Johnson & Johnson$394
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 106 | $1,590 |
| Novo Nordisk | 99 | $1,472 |
| Lilly USA, LLC | 41 | $616 |
| Amgen | 33 | $496 |
| Pfizer | 30 | $414 |
| Johnson & Johnson | 18 | $394 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $272 |
| GSK | 14 | $228 |
| Axsome Therapeutics, Inc. | 11 | $219 |
| Merck | 10 | $179 |
| Phathom Pharmaceuticals, Inc. | 8 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $155 |
| Astellas Pharma US Inc | 10 | $150 |
| Exact Sciences | 9 | $145 |
| Optinose US, Inc. | 1 | $125 |
| Boehringer Ingelheim | 6 | $111 |
| AstraZeneca | 8 | $110 |
| Azurity Pharmaceuticals, Inc. | 6 | $93 |
| Bayer | 6 | $91 |
| Lundbeck LLC | 4 | $74 |
| Kowa Pharmaceuticals America, Inc. | 5 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $64 |
| Abbott | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 1 | $50 |
| Amarin Pharma, Inc. | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Dexcom, Inc. | 2 | $29 |
| Endo Pharmaceuticals Inc. | 2 | $26 |
| Nevro Corp. | 1 | $24 |
| Eisai Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,566 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $39,948 |
| XareltoRivaroxaban | 15 | $12,520 |
| FarxigaDapagliflozin Propanediol | 12 | $11,118 |
| JardianceEmpagliflozin | 14 | $10,727 |
| LinzessLinaclotide | 13 | $10,002 |
| JanuviaSitagliptin Phosphate | 15 | $8,046 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,531 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,123 |
| BenicarOlmesartan Medoxomil | 12 | $4,904 |
| DilantinPhenytoin Sodium Extended | 11 | $2,036 |
| Valsartan | 31 | $1,643 |
| Atorvastatin Calcium | 161 | $1,286 |
| Duloxetine Hcl | 46 | $1,215 |
| Metoprolol Succinate | 54 | $988 |
| Levothyroxine Sodium | 108 | $968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,472 | $39,94829 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $111 | $17,25827 claims |
| Johnson & JohnsonXarelto | $394 | $12,52015 claims |
| AstraZenecaFarxiga | $110 | $11,11812 claims |
| AbbVieLinzess, Synthroid | $1,590 | $10,88329 claims |
| MerckJanuvia | $179 | $8,04615 claims |
| GSKAnoro Ellipta | $228 | $5,12311 claims |
| PfizerDilantin | $414 | $2,03611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $968108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Crestwood
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.